Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
This is a single center study to assess the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma in China.
Multiple Myeloma
DRUG: IM21 CAR-T cells
Incidence of adverse events within 1 month after CAR-T cell infusion, The primary endpoint wasIncidence of adverse events within 1 month after CAR-T cell infusion, 30days
Objective Response Rate(ORR) at 90 days, 90days
In this study, about 10 patients with relapsed or refractory multiple myeloma aged â‰¥60 years were recruited for IM21 CAR-T cell single transfusion therapy. The safety and tolerability of the treatment were evaluated, and the curative effect was initially observed. The research plan includes five stages: screening stage, cell collection stage, chemotherapy pretreatment stage, infusion stage and follow-up stage.